New insights in mucosal vaccine development
- PMID: 22085556
- DOI: 10.1016/j.vaccine.2011.11.003
New insights in mucosal vaccine development
Abstract
Mucosal surfaces are the major entrance for infectious pathogens and therefore mucosal immune responses serve as a first line of defence. Most current immunization procedures are obtained by parenteral injection and only few vaccines are administered by mucosal route, because of its low efficiency. However, targeting of mucosal compartments to induce protective immunity at both mucosal sites and systemic level represents a great challenge. Major efforts are made to develop new mucosal candidate vaccines by selecting appropriate antigens with high immunogenicity, designing new mucosal routes of administration and selecting immune-stimulatory adjuvant molecules. The aim of mucosal vaccines is to induce broad potent protective immunity by specific neutralizing antibodies at mucosal surfaces and by induction of cellular immunity. Moreover, an efficient mucosal vaccine would make immunization procedures easier and be better suited for mass administration. This review focuses on contemporary developments of mucosal vaccination approaches using different routes of administration.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Similar articles
-
Mucosal delivery of vaccine antigens and its advantages in pediatrics.Adv Drug Deliv Rev. 2006 Apr 20;58(1):52-67. doi: 10.1016/j.addr.2006.01.002. Epub 2006 Mar 3. Adv Drug Deliv Rev. 2006. PMID: 16516335 Review.
-
Defending the mucosa: adjuvant and carrier formulations for mucosal immunity.Curr Opin Immunol. 2011 Jun;23(3):414-20. doi: 10.1016/j.coi.2011.03.009. Epub 2011 Apr 19. Curr Opin Immunol. 2011. PMID: 21511452 Review.
-
Delivery systems: a vaccine strategy for overcoming mucosal tolerance?Expert Rev Vaccines. 2009 Jan;8(1):103-12. doi: 10.1586/14760584.8.1.103. Expert Rev Vaccines. 2009. PMID: 19093777 Review.
-
Optimizing efficacy of mucosal vaccines.Expert Rev Vaccines. 2012 Sep;11(9):1139-55. doi: 10.1586/erv.12.81. Expert Rev Vaccines. 2012. PMID: 23151169 Review.
-
Mucosal vaccines: a paradigm shift in the development of mucosal adjuvants and delivery vehicles.APMIS. 2015 Apr;123(4):275-88. doi: 10.1111/apm.12351. Epub 2015 Jan 29. APMIS. 2015. PMID: 25630573 Review.
Cited by
-
E2 multimeric scaffold for vaccine formulation: immune response by intranasal delivery and transcriptome profile of E2-pulsed dendritic cells.BMC Microbiol. 2016 Jul 16;16(1):152. doi: 10.1186/s12866-016-0772-x. BMC Microbiol. 2016. PMID: 27421762 Free PMC article.
-
Proof of concept in utilizing in-trans surface display system of Lactobacillus plantarum as mucosal tuberculosis vaccine via oral administration in mice.BMC Biotechnol. 2018 Oct 11;18(1):63. doi: 10.1186/s12896-018-0461-y. BMC Biotechnol. 2018. PMID: 30309359 Free PMC article.
-
Intranasal vaccination promotes detrimental Th17-mediated immunity against influenza infection.PLoS Pathog. 2014 Jan;10(1):e1003875. doi: 10.1371/journal.ppat.1003875. Epub 2014 Jan 23. PLoS Pathog. 2014. PMID: 24465206 Free PMC article.
-
Yeast oral vaccines against infectious diseases.Front Microbiol. 2023 Apr 17;14:1150412. doi: 10.3389/fmicb.2023.1150412. eCollection 2023. Front Microbiol. 2023. PMID: 37138614 Free PMC article. Review.
-
Immunological Insights and Therapeutic Advances in COPD: Exploring Oral Bacterial Vaccines for Immune Modulation and Clinical Improvement.Vaccines (Basel). 2025 Jan 22;13(2):107. doi: 10.3390/vaccines13020107. Vaccines (Basel). 2025. PMID: 40006655 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical